Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman John Yu, MD, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte New York Palace Hotel. The presentation is expected to highlight the company’s innovative approach to oncology therapeutics, particularly its lead candidate ENV-105.
The significance of this presentation lies in the growing need for therapies that address drug resistance, a major hurdle in cancer treatment. Kairos Pharma is leveraging structural biology to target CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This approach could potentially change the treatment landscape for patients who have limited options after their cancers become resistant to existing drugs.
According to the company, ENV-105 is designed to bind to CD105 and disrupt the signaling pathways that enable tumor cells to evade treatment. This mechanism is distinct from traditional chemotherapies and immunotherapies, offering a novel way to combat resistance. The presentation at the H.C. Wainwright conference provides a platform for Kairos Pharma to update investors and industry stakeholders on the development progress and future plans for ENV-105.
The conference, a prominent event in the investment community, attracts institutional investors, analysts, and biotech executives. For Kairos Pharma, this is an opportunity to showcase its science and articulate its strategic vision. The company’s focus on drug resistance is particularly timely, as many approved cancer therapies eventually lose effectiveness, leading to disease progression. By addressing this unmet medical need, Kairos Pharma could position itself as a key player in the next wave of oncology innovation.
Investors and analysts will be keen to hear about the clinical development timeline for ENV-105, including any updates on ongoing trials or regulatory milestones. The company’s use of structural biology to design antibodies is a sophisticated approach that may yield more targeted and effective therapies. If successful, ENV-105 could become an important addition to combination regimens, potentially enhancing outcomes for patients with hard-to-treat cancers.
Kairos Pharma, based in Los Angeles, is at the forefront of this research. The company’s newsroom provides additional updates on its progress, and the full press release regarding the conference presentation is available online. As the conference approaches, the biopharmaceutical community will be watching closely to see what insights Dr. Yu shares about the future of cancer drug resistance mitigation.
